Seer (NASDAQ:SEER – Get Rating) is one of 43 publicly-traded companies in the “Analytical instruments” industry, but how does it weigh in compared to its peers? We will compare Seer to similar businesses based on the strength of its valuation, profitability, dividends, analyst recommendations, earnings, risk and institutional ownership.
This table compares Seer and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This table compares Seer and its peers gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Seer||$6.62 million||-$71.17 million||-5.83|
|Seer Competitors||$1.16 billion||$344.59 million||-25.60|
Seer’s peers have higher revenue and earnings than Seer. Seer is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Institutional and Insider Ownership
86.9% of Seer shares are held by institutional investors. Comparatively, 61.5% of shares of all “Analytical instruments” companies are held by institutional investors. 28.9% of Seer shares are held by company insiders. Comparatively, 13.6% of shares of all “Analytical instruments” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
This is a summary of current ratings and price targets for Seer and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Seer presently has a consensus target price of $21.00, indicating a potential upside of 183.78%. As a group, “Analytical instruments” companies have a potential upside of 38.33%. Given Seer’s higher probable upside, equities analysts plainly believe Seer is more favorable than its peers.
Volatility & Risk
Seer has a beta of 3.13, meaning that its stock price is 213% more volatile than the S&P 500. Comparatively, Seer’s peers have a beta of 1.18, meaning that their average stock price is 18% more volatile than the S&P 500.
Seer peers beat Seer on 8 of the 13 factors compared.
Seer Company Profile (Get Rating)
Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It has a collaboration agreement with Discovery Life Sciences, LLC. and the Salk Institute for Biological Studies. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
Receive News & Ratings for Seer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seer and related companies with MarketBeat.com's FREE daily email newsletter.